Resistance among Streptococcus pneumoniae: Implications for drug selection.

@article{Appelbaum2002ResistanceAS,
  title={Resistance among Streptococcus pneumoniae: Implications for drug selection.},
  author={PeterC. Appelbaum},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2002},
  volume={34 12},
  pages={
          1613-20
        }
}
Streptococcus pneumoniae is an important pathogen in many community-acquired respiratory infections in the United States and a leading cause of morbidity and mortality worldwide. Unfortunately, S. pneumoniae is becoming increasingly resistant to a variety of antibiotics. Results of recent surveillance studies in the United States show that the prevalence of penicillin-nonsusceptible S. pneumoniae ranges from 25% to >50%, and rates of macrolide resistance among pneumococci are reported to be as… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 91 CITATIONS

FILTER CITATIONS BY YEAR

2003
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

  • Averaged 3 Citations per year over the last 3 years

  • 14% Increase in citations per year in 2018 over 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 74 REFERENCES

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin

  • TM JrFile, B Schlemmer, J Garau, M Cupo, C. Young
  • Clinical Study Group. J Antimicrob Chemother
  • 2001

Similar Papers

Loading similar papers…